Bristol-Myers, QIMR to discover new immuno-oncology antibodies

QIMR is focused on research of cancer, infectious diseases, mental health and a range of complex disorders.

As part of the deal, BMS will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration.

Bristol-Myers Squibb R&D head of Discovery Carl Decicco said: "Bristol-Myers Squibb continues to invest in strategic partnerships that accelerate the discovery and development of novel immunotherapies through innovative science and technologies.

"We are excited to work with QIMR Berghofer Medical Research Institute, a partner that brings significant experience and expertise in cancer research."

In order to address the unmet medical need, BMS is carrying out research in a new field of cancer research and treatment called immuno-oncology, which includes agents whose primary mechanism is to work directly with the body’s immune system to combat cancer.

QIMR Berghofer director and CEO Professor Frank Gannon said: "QIMR Berghofer is committed to translational research, so it is gratifying when high quality research at the Institute results in the strategic collaboration announced today.

"Bristol-Myers Squibb is the ideal partner to progress these assets to the clinic, with their world-leading expertise in immuno-oncology and a proven track record developing multiple cancer therapies on the market.

"We look forward to a fruitful, long-term collaboration, delivering new therapies for cancer patients."

Currently, BMS is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer, including researching the potential of combining immuno-oncology agents that target different pathways to treat cancer.

Image: BMS and QIMR will discover new therapeutic antibodies against an undisclosed immuno-oncology target. Photo: courtesy of Baitong333/ FreeDigitalPhotos.net